Sargramostim
Sargramostim
Definition
A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
Also known as 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SARGRAMOSTIM — per NCIT
Also identified as
- ATC L03AA09 per RXNORM
- NCIT NCIT:C1492 per NCIT
- SCTID 108967001 per RXNORM
- SCTID 388375003 per RXNORM
- UNII 5TAA004E22 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Breast neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Hodgkins lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
| Neutropenia | may treat | MEDRT · Public domain (U.S. Government work) |
| Non-Hodgkin lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.